@article{Wells_D-2022_151148,
title = {Human seasonal coronavirus neutralization and COVID‐19 severity},
author = {Wells, D. and Cantoni, D. and Mayora-Neto, M. and Genova, C. and Sampson, A. and Ferrari, M. and Carnell, G. and Nadesalingam, A. and Smith, P. and Chan, A. and Raddi, G. and Castillo-Olivares, J. and Baxendale, H. and Temperton, N. and Heeney, J.},
month = {jun},
year = {2022},
abstract = {The virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for the global coronavirus disease-2019 (COVID-19) pandemic, spread rapidly around the world causing high morbidity and mortality. However, there are four known, endemic seasonal coronaviruses in humans (HCoVs), and whether antibodies for these HCoVs play a role in severity of COVID-19 disease has generated a lot of interest. Of these seasonal viruses NL63 is of particular interest as it uses the same cell entry receptor as SARS-CoV-2. We use functional, neutralizing assays to investigate cross-reactive antibodies and their relationship with COVID-19 severity. We analyzed the neutralization of SARS-CoV-2, NL63, HKU1, and 229E in 38 COVID-19 patients and 62 healthcare workers, and a further 182 samples to specifically study the relationship between SARS-CoV-2 and NL63. We found that although HCoV neutralization was very common there was little evidence that these antibodies neutralized SARS-CoV-2. Despite no evidence in cross-neutralization, levels of NL63 neutralizing antibodies become elevated after exposure to SARS-CoV-2 through infection or following vaccination.},
pages = {4820-4829},
volume = {94},
issue = {10},
journal = {Journal of Medical Virology},
publisher = {Wiley},
url = {https://doi.org/10.1002/jmv.27937},
}
